These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 1692253

  • 1. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression.
    Mills GB, Zhang N, May C, Hill M, Chung A.
    Cancer Res; 1990 May 15; 50(10):3036-42. PubMed ID: 1692253
    [Abstract] [Full Text] [Related]

  • 2. Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors.
    Chu JW, Sharom FJ.
    Immunology; 1993 May 15; 79(1):10-7. PubMed ID: 8509130
    [Abstract] [Full Text] [Related]

  • 3. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM.
    Clin Cancer Res; 1996 Dec 15; 2(12):1951-9. PubMed ID: 9816154
    [Abstract] [Full Text] [Related]

  • 4. Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4-induced mitogenic response.
    Leland P, Obiri N, Aggarwal BB, Puri RK.
    Oncol Res; 1995 Dec 15; 7(5):227-35. PubMed ID: 8534928
    [Abstract] [Full Text] [Related]

  • 5. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism.
    Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT.
    J Pharmacol Exp Ther; 1995 Jan 15; 272(1):460-8. PubMed ID: 7529314
    [Abstract] [Full Text] [Related]

  • 6. Functional properties of the 50 kd protein associated with the E-receptor on human T lymphocytes: suppression of IL 2 production by anti-p50 monoclonal antibodies.
    Tadmori W, Reed JC, Nowell PC, Kamoun M.
    J Immunol; 1985 Mar 15; 134(3):1709-16. PubMed ID: 2981919
    [Abstract] [Full Text] [Related]

  • 7. Role of protein kinase C in interleukin 1, anti-T3, and mitogenic lectin-induced interleukin 2 secretion.
    Mills GB, May C, Hill M, Gelfand EW.
    J Cell Physiol; 1989 Nov 15; 141(2):310-7. PubMed ID: 2808540
    [Abstract] [Full Text] [Related]

  • 8. Tyrosine phosphorylation is an obligatory event in IL-2 secretion.
    Stanley JB, Gorczynski R, Huang CK, Love J, Mills GB.
    J Immunol; 1990 Oct 01; 145(7):2189-98. PubMed ID: 1697878
    [Abstract] [Full Text] [Related]

  • 9. The lymphokine "inhibitor of DNA synthesis" (IDS) suppresses human T lymphocyte proliferation by an interleukin-2-independent mechanism.
    Reed JC, Jegasothy BV, Batra BK, Weidenfeld J, Smith DR, Nowell PC.
    Lymphokine Res; 1986 Oct 01; 5(1):11-20. PubMed ID: 3484797
    [Abstract] [Full Text] [Related]

  • 10. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A, Fuson T, Yang X, Kays J, Moxham C, Zartler E, Chandrashekhar S, Galvin RJ.
    Bone; 2005 Feb 01; 36(2):284-91. PubMed ID: 15780954
    [Abstract] [Full Text] [Related]

  • 11. Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor.
    Paliogianni F, Ahuja SS, Balow JP, Balow JE, Boumpas DT.
    J Immunol; 1993 Oct 15; 151(8):4081-9. PubMed ID: 8409387
    [Abstract] [Full Text] [Related]

  • 12. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
    Kasayama S, Saito H, Kouhara H, Sumitani S, Sato B.
    J Cell Physiol; 1993 Feb 15; 154(2):254-61. PubMed ID: 7678839
    [Abstract] [Full Text] [Related]

  • 13. Suppression of antigen-specific T cell responses by Leishmania major excreted factor: inhibition of activation signals linked to the T cell antigen receptor and interleukin 2 receptor.
    Isakov N, Tamir A, el-On J.
    Isr J Med Sci; 1994 Sep 15; 30(9):673-9. PubMed ID: 8088978
    [Abstract] [Full Text] [Related]

  • 14. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
    Kasid A, Bell GI, Director EP.
    J Immunol; 1988 Jul 15; 141(2):690-8. PubMed ID: 3133414
    [Abstract] [Full Text] [Related]

  • 15. Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.
    Sartor O, McLellan CA, Myers CE, Borner MM.
    J Clin Invest; 1992 Dec 15; 90(6):2166-74. PubMed ID: 1281826
    [Abstract] [Full Text] [Related]

  • 16. Thrombin enhances T cell proliferative responses and cytokine production.
    Naldini A, Carney DH, Bocci V, Klimpel KD, Asuncion M, Soares LE, Klimpel GR.
    Cell Immunol; 1993 Apr 01; 147(2):367-77. PubMed ID: 8453678
    [Abstract] [Full Text] [Related]

  • 17. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells.
    Coffey RJ, Leof EB, Shipley GD, Moses HL.
    J Cell Physiol; 1987 Jul 01; 132(1):143-8. PubMed ID: 3496343
    [Abstract] [Full Text] [Related]

  • 18. The suppressive effect of gangliosides upon IL 2-dependent proliferation as a function of inhibition of IL 2-receptor association.
    Robb RJ.
    J Immunol; 1986 Feb 01; 136(3):971-6. PubMed ID: 3079806
    [Abstract] [Full Text] [Related]

  • 19. Suramin binds to platelet-derived growth factor and inhibits its biological activity.
    Hosang M.
    J Cell Biochem; 1985 Feb 01; 29(3):265-73. PubMed ID: 4077932
    [Abstract] [Full Text] [Related]

  • 20. Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.
    Estrov Z, Talpaz M, Estey EH, Strassmann G.
    Exp Hematol; 1995 Sep 01; 23(10):1080-7. PubMed ID: 7544738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.